ZW 25Alternative Names: HER2 inhibitor; ZW25
Latest Information Update: 20 Feb 2017
At a glance
- Originator Zymeworks
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer
- Preclinical Breast cancer; Gastric cancer